Advertisement

Topics

[News] Labetuzumab govitecan in metastatic colorectal cancer

02:10 EDT 25 Aug 2017 | The Lancet

Labetuzumab govitecan monotherapy might be safe and effective in patients with relapsed or refractory metastatic colorectal cancer previously treated with irinotecan-containing therapy.

Original Article: [News] Labetuzumab govitecan in metastatic colorectal cancer

NEXT ARTICLE

More From BioPortfolio on "[News] Labetuzumab govitecan in metastatic colorectal cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...